Compare · Nootropic peptide
Dihexa vs Semax
Both are nootropic peptide compounds. Here's how they line up on the evidence — graded the same way.
| Dihexa | Semax | |
|---|---|---|
| Evidence | Animal only | Preliminary human |
| Class | Nootropic peptide | Nootropic peptide |
| Summary | An angiotensin IV-derived oligopeptide studied in animals for synaptogenesis and cognition; it has never been tested in humans, and its foundational mechanism paper was retracted in 2025. | A Russian-approved nootropic/neuroprotective peptide whose human evidence is real but small, mostly Russian-language, and methodologically thin. |
| Full profile → | Full profile → |
Dihexa
Dihexa is a small angiotensin IV-derived peptide that drew attention for animal data on dendritic spine growth and learning, plus an eye-catching claim that it is many orders of magnitude more potent than BDNF. It is sold online as a nootropic, but the honest picture is far more cautious than the…
Semax
Semax is a synthetic peptide developed in Russia in the late 1980s and used there as a prescription drug for stroke and cognitive disorders. It is not approved anywhere in the West, and most of the research is in Russian.